Seaport Therapeutics, Inc.
SPTX Nasdaq
SEC CIK 2042347
Follow Seaport Therapeutics
Weekly email: filings, results
Net income
−$26.4M
−17.1% vs same quarter last year
EPS, diluted
−$0.49
+94.8% vs same quarter last year
Operating cash flow
−$22.7M
−43.9% vs same quarter last year
Operating income
−$30.3M
−19.3% vs same quarter last year
Source: SEC XBRL filings · latest filing